{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:00:05Z","timestamp":1780725605940,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023\\u201328"],"award-info":[{"award-number":["2023\\u201328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82074077"],"award-info":[{"award-number":["82074077"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474130"],"award-info":[{"award-number":["82474130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010849","name":"Wuhan Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cbi.2025.111737","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:52:08Z","timestamp":1757346728000},"page":"111737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Celecoxib blocks AKT\/mTOR in AKT\/YapS127A-driven intrahepatic cholangiocarcinoma, activating p21\/p27 for cycle arrest and suppressing Mcl-1 for apoptosis"],"prefix":"10.1016","volume":"421","author":[{"given":"Xiangyun","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-8983","authenticated-orcid":false,"given":"Zhenpeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111737_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbi.2025.111737_bib2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cbi.2025.111737_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhepr.2019.06.003","article-title":"Immunobiology of cholangiocarcinoma","volume":"1","author":"Loeuillard","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.cbi.2025.111737_bib4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","article-title":"Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes","volume":"35","author":"Xue","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cbi.2025.111737_bib5","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cbi.2025.111737_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2025.111737_bib7","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2025.111737_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma \u2014 evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cbi.2025.111737_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13046-022-02283-8","article-title":"CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype","volume":"41","author":"Mancarella","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cbi.2025.111737_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2016.05.019","article-title":"Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models","volume":"223","author":"Doussot","year":"2016","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.cbi.2025.111737_bib12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2353\/ajpath.2010.090477","article-title":"Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications","volume":"176","author":"Badve","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cbi.2025.111737_bib13","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.cbi.2025.111737_bib14","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cellsig.2008.11.015","article-title":"Function of Akt\/PKB signaling to cell motility, invasion and the tumor stroma in cancer","volume":"21","author":"Chin","year":"2009","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cbi.2025.111737_bib15","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2217\/fon.11.95","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in hepatocellular carcinoma","volume":"7","author":"Zhou","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.cbi.2025.111737_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cbi.2025.111737_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","article-title":"Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors","volume":"32","author":"Ewald","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2025.111737_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12885-016-2360-8","article-title":"Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts","volume":"16","author":"Heits","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cbi.2025.111737_bib19","article-title":"Potentiation of the anticancer effects of everolimus using a dual mTORC1\/2 inhibitor in hepatocellular carcinoma cells","volume":"8","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2025.111737_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/onc.2015.79","article-title":"mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation","volume":"35","author":"He","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2025.111737_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","article-title":"Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice","volume":"67","author":"Zhang","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cbi.2025.111737_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106379","article-title":"A journey of celecoxib from pain to cancer","volume":"147","author":"Saxena","year":"2020","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.cbi.2025.111737_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in cancer therapy and prevention - review","volume":"20","author":"Toloczko-Iwaniuk","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cbi.2025.111737_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022544","article-title":"The molecular mechanisms of celecoxib in tumor development","volume":"99","author":"Wen","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.cbi.2025.111737_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in cancer therapy and prevention \u2013 review","volume":"20","author":"To\u0142oczko-Iwaniuk","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.cbi.2025.111737_bib26","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M201119200","article-title":"Celecoxib induces apoptosis by inhibiting 3-Phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line","volume":"277","author":"Arico","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111737_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/94.8.585","article-title":"Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells","volume":"94","author":"Song","year":"2002","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.cbi.2025.111737_bib28","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.3171\/foc.2006.20.4.14","article-title":"Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy","volume":"20","author":"Sch\u00f6nthal","year":"2006","journal-title":"Neurosurgical Focus FOC"},{"key":"10.1016\/j.cbi.2025.111737_bib29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-03-2396","article-title":"3-Phosphoinositide-Dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells","volume":"64","author":"Kulp","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/gut.48.1.80","article-title":"Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma","volume":"48","author":"Chariyalertsak","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cbi.2025.111737_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.humpath.2012.09.004","article-title":"Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma","volume":"44","author":"Aishima","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.cbi.2025.111737_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bone.2010.09.020","article-title":"Constitutively expressed COX-2 in osteoblasts positively regulates Akt signal transduction via suppression of PTEN activity","volume":"48","author":"Li","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.cbi.2025.111737_bib33","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3892\/or.2014.3093","article-title":"Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN\/PI3K\/Akt\/HIF-1 pathway in an H22 murine hepatocarcinoma model","volume":"31","author":"Sui","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2025.111737_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2006.11.032","article-title":"Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt\/GSK3beta\/NAG-1 pathway","volume":"251","author":"Pang","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2025.111737_bib35","article-title":"Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt\/mTOR signaling pathway and COX-2 expression","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2025.111737_bib36","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/bcr1294","article-title":"Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours","volume":"7","author":"Kucab","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/1535-7163.299.3.3","article-title":"The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells","volume":"3","author":"Wu","year":"2004","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2025.111737_bib38","first-page":"265","article-title":"Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3","volume":"2","author":"Lai","year":"2003","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2025.111737_bib39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/hep.20143","article-title":"Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation","volume":"39","author":"Zhang","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cbi.2025.111737_bib40","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.gastro.2010.12.006","article-title":"Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma","volume":"140","author":"Calvisi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbi.2025.111737_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2022.2045875","article-title":"Usutu Virus escapes langerin-induced restriction to productively infect human Langerhans cells, unlike West Nile virus","volume":"11","author":"Martin","year":"2022","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.cbi.2025.111737_bib42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cbi.2025.111737_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41419-021-03500-6","article-title":"The application of BH3 mimetics in myeloid leukemias","volume":"12","author":"Parry","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cbi.2025.111737_bib44","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1158\/0008-5472.CAN-06-3964","article-title":"Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib45","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-10-4531","article-title":"Akt-dependent glucose metabolism promotes mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition","volume":"71","author":"Coloff","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110397","article-title":"Dual PI3K\/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy","volume":"129","author":"Hu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cbi.2025.111737_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2009.07.021","article-title":"Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis","volume":"79","author":"Rudner","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111737_bib48","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bcp.2008.08.012","article-title":"Importance of Bak for celecoxib-induced apoptosis","volume":"76","author":"Muller","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111737_bib49","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cbi.2017.05.012","article-title":"Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2","volume":"272","author":"Mosaad","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2025.111737_bib50","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"Hidalgo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2025.111737_bib51","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.cbi.2025.111737_bib52","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-03-1086","article-title":"Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1\/cip1 and p27kip1 and cell cycle arrest","volume":"64","author":"Han","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib53","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3892\/ijmm.2014.1713","article-title":"Celecoxib regulates apoptosis and autophagy via the PI3K\/Akt signaling pathway in SGC-7901 gastric cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cbi.2025.111737_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/nu16173020","article-title":"Parecoxib enhances resveratrol against human colorectal cancer cells through Akt and TXNDC5 inhibition and MAPK regulation","author":"Chang","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.cbi.2025.111737_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2025.111737_bib56","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1128\/MCB.19.9.6195","article-title":"The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase\/Akt signaling pathway through a transcription factor complex containing CREB","volume":"19","author":"Wang","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.cbi.2025.111737_bib57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"Longo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2025.111737_bib58","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.bbamcr.2015.05.014","article-title":"Oncostatin M-dependent Mcl-1 induction mediated by JAK1\/2-STAT1\/3 and CREB contributes to bioenergetic improvements and protective effects against mitochondrial dysfunction in cortical neurons","volume":"1853","author":"Chang","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.cbi.2025.111737_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-017-0169-2","article-title":"Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cbi.2025.111737_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1158\/1541-7786.MCR-18-0650","article-title":"Repurposing of mTOR complex inhibitors attenuates MCL-1 and sensitizes to PARP inhibition","volume":"17","author":"Mattoo","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cbi.2025.111737_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110397","article-title":"Dual PI3K\/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy","volume":"129","author":"Hu","year":"2020","journal-title":"Biomed. Pharmacother."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725003679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725003679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:04:06Z","timestamp":1780722246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725003679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"alternative-id":["S0009279725003679"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111737","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Celecoxib blocks AKT\/mTOR in AKT\/YapS127A-driven intrahepatic cholangiocarcinoma, activating p21\/p27 for cycle arrest and suppressing Mcl-1 for apoptosis","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111737"}}